The make-up of the gut microbiome may be linked to a person’s risk of developing ‘long COVID’ many months after initial infection with SARS-CoV-2, the virus responsible for COVID-19 infection, suggests research published online in the journal Gut.
Blocking a key protein found in Anopheles gambiae mosquitoes—the principal vector for malaria transmission to humans in Africa—could thwart infection with malaria parasites and thus prevent them from transmitting the parasites to humans, according to a study from researchers at the Johns Hopkins Malaria Research Institute at the Johns Hopkins Bloomberg School of Public Health.
Here are some of the latest articles we've posted in the Behavioral Science channel.
Many experts now predict that COVID-19, which so far has killed more than 5.5 million people worldwide, will remain endemic as new, infectious variants of SARS-CoV-2 emerge.
New laboratory research from Oregon Health & Science University reveals more than one path toward robust immunity from COVID-19.
The latest research news from the Health Disparities Channel.
Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2. These T cells can recognize SARS-CoV-2 Variants of Concern, including Delta and Omicron.
The Global Virus Network (GVN), representing 66 Centers of Excellence and 10 Affiliates in 35 countries comprising foremost experts in every class of virus causing disease in humans, and the Institute of Biomedical Systems and Biotechnologies at Peter the Great St. Petersburg Polytechnic University (SPbPU) announced the addition of the Institute as GVN’s newest Center of Excellence.
Studies since the start of the pandemic have noted that pigs exposed to the coronavirus don’t show clinical signs of disease nor do they transmit the virus to other animals. Iowa State University scientists have uncovered important clues that shed light on why pigs don’t get sick, and the discovery could lead to better treatments for COVID-19 in humans.
A study by researchers at Mayo Clinic Cancer Center has found that patients with cancer who receive chemotherapy ― and some targeted therapies, such as CDK4/6 inhibitors and therapies targeted at B cells ― may mount an inadequate immune response to COVID-19 vaccination. The findings are published in Mayo Clinic Proceedings.
The omicron variant can partly evade the antibody response provided by vaccination or infection with previous variants of SARS-CoV-2.
La Jolla Institute for Immunology (LJI) and Kyowa Kirin, Inc. (KKNA), a wholly-owned subsidiary of Kyowa Kirin Co., Ltd (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company, today announced the signing of a new collaboration agreement. The agreement marks another milestone in one of the most enduring industry-academic collaborations in the world.
A new study by Wistar researchers has identified a new potential pathway for developing therapeutics that target Epstein-Barr virus (EBV).
A new study from Washington University School of Medicine in St. Louis shows that treatment with an immune-boosting protein called interleukin 7 (IL-7) in combination with radiation improves survival in mice with glioblastoma. The study in mice suggests promise for a phase 1/2 clinical trial at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine that is investigating a long-acting type of IL-7 in patients with glioblastoma.
Researchers studying how small worms defend themselves against pathogens have discovered a gene that acts as a first-line response against infection. They identified “ZIP-1” as a centralized hub for immune response, a finding could have implications for understanding human immunity against viruses.
A new study published Jan. 13 in Science reports that Epstein-Barr virus infection – known for causing mononucleosis or “mono,” could be a primary cause for multiple sclerosis.
An artery is not like a nose. Or is it? Scientists at La Jolla Institute for Immunology (LJI) have discovered that immune cells in arteries can "sniff" out their surroundings and cause inflammation.
The human immune system, that marvel of complexity, subtlety, and sophistication, includes a billion-year-old family of proteins used by bacteria to defend themselves against viruses, scientists at Dana-Farber Cancer Institute and in Israel have discovered.
A new, targeted therapy, developed by researchers from the Azrieli Faculty of Medicine of Bar-Ilan University, the Albert Einstein College of Medicine, the University of Houston, and the pharmaceutical company Equillium, together with several other academic collaborators, inhibits specific immune cells associated with lupus nephritis, and was effective in improving kidney inflammation in animal models of lupus and lupus nephritis. The new approach could serve as an alternative to current treatments targeting multiple immune cells, and provide a more effective and potentially personalized remedy for lupus nephritis. The development was recently reported in the Journal of Clinical Investigation.
Tertiary lymphoid structures are formations that occur outside of the lymphatic system. They contain immune cells and are similar in structure and function to lymph nodes and other lymphoid structures. However, little is known about how tertiary lymphoid structures form. In a new article published in Immunity, Moffitt Cancer Center researchers report on the molecular and cellular mechanisms that control tertiary lymphoid structure formation within tumors.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
